Results 21 to 30 of about 226,969 (309)

Industry-scale application and evaluation of deep learning for drug target prediction [PDF]

, 2019
Artificial intelligence (AI) is undergoing a revolution thanks to the breakthroughs of machine learning algorithms in computer vision, speech recognition, natural language processing and generative modelling.
Ashby, Thomas J., Böhm, Stanislav, Ceulemans, Hugo, Chen, Hongming, Chupakhin, Vladimir, Cima, Vojtěch, Engkvist, Ola, Golib-Dzib, Jose-Felipe, Greene, Nigel, Hochreiter, Sepp, Jeliazkova, Nina, Klambauer, Günter, Martinovič, Jan, Mayr, Andreas, Sturm, Noe, Van, Thanh Le, Vander Aa, Tom, Vandriessche, Yves, Wegner, Joerg   +18 more
core   +2 more sources

Thrombotic Adverse Events Reported for Moderna, Pfizer and Oxford-AstraZeneca COVID-19 Vaccines: Comparison of Occurrence and Clinical Outcomes in the EudraVigilance Database

Vaccines, 2021
Vaccination against COVID-19 is the cornerstone of controlling and mitigating the ongoing pandemic. Thrombotic adverse events linked to Moderna, Pfizer and the Oxford-AstraZeneca vaccine have been documented and described as extremely rare.
Mansour Tobaiqy, Katie MacLure, Hajer Elkout, Derek Stewart   +3 more
doaj   +1 more source

Does hemispheric lateralization influence functional and cardiovascular outcomes after stroke?: an analysis of placebo-treated patients from prospective acute stroke trials [PDF]

, 2008
<p><b>Background and Purpose:</b> The influence of stroke lateralization on functional and cardiovascular outcome after stroke is not well established.
Fink, J.N., Frampton, C.M., Lees, K.R., Lyden, P.   +3 more
core   +1 more source

Additional outcomes and subgroup analyses of NXY-059 for acute ischemic stroke in the SAINT I trial [PDF]

, 2006
<p><b>Background and Purpose:</b> NXY-059 is a free radical-trapping neuroprotectant demonstrated to reduce disability from ischemic stroke. We conducted analyses on additional end points and sensitivity analyses to confirm our findings.
Ashwood, T., Davalos, A., Davis, S.M., Diener, H.-C., Emeribe, U., Grotta, J., Hardemark, H.G., Lees, K.R., Lyden, P., Shuaib, A., Wasiewski, W., Zivin, J.A.   +11 more
core   +1 more source

Baseline characteristics and enrichment results from the SONAR trial [PDF]

, 2018
Aim: The SONAR trial uses an enrichment design based on the individual response to the selective endothelin receptor antagonist atrasentan on efficacy (the degree of the individual response in the urinary albumin‐to‐creatinine ratio [UACR]) and safety/
Andress, Dennis L., Bakris, George, Brennan, John J., Correa-Rotter, Ricardo, de Zeeuw, Dick, Heerspink, Hiddo J.L., Hou, Fan Fan, Kitzman, Dalane W., Kohan, Donald, Makino, Hirofumi, McMurray, John, Parving, Hans-Henrik, Perkovic, Vlado, Tobe, Sheldon, Wigderson, Melissa, Yi, Tingting   +15 more
core   +3 more sources

Association of circulating protein biomarkers with clinical outcomes of durvalumab in head and neck squamous cell carcinoma

OncoImmunology, 2021
The potential for durvalumab, a programmed cell death ligand-1 (PD-L1)-blocking monoclonal antibody, to treat head and neck squamous cell carcinoma (HNSCC) is being evaluated in multiple clinical trials.
Rosalinda Arends, Xiang Guo, Paul G. Baverel, Ignacio González-García, James Xie, Nassim Morsli, Alejandro Yovine, Lorin K. Roskos   +7 more
doaj   +1 more source

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. [PDF]

, 2017
Cancer immunotherapy has transformed the treatment of cancer. However, increasing use of immune-based therapies, including the widely used class of agents known as immune checkpoint inhibitors, has exposed a discrete group of immune-related adverse ...
Abdallah, K., Anderson, J., Andrews, S., Arrindell, D., Ballesteros, J., Bingham, C. O., Boyer, J., Brogdon, C., Chen, D., Chonzi, D., Cotarla, I., Cunha, R., Dadu, R., Davies, M., Dawson, M., Diab, A., Dicker, Adam, Eifler, L., Ernstoff, M. S., Ferguson, A., Ferlini, C., Frankel, S., Go, W., Gochett, C., Goldberg, J., Goncalves, P., Goswami, T., Gregory, N., Gulley, J. L., Hamad, L., Hayreh, V., Helie, N., Holmes, W., Hsu, J. Y., Ibrahim, R., Kaufman, H. L., Kim, S., Lacouture, M. E., Lambotte, O., Larocca, C., LeBoeuf, N. R., Lehman, K., Lenihan, D., Ley-Acosta, S., Luke, J., McClure, J., Michelon, E., Nakamura, M., Onofrei, C., Patel, K., Piperdi, B., Puzanov, I., Rasheed, Z., Reshef, D., Riemer, J., Robert, C., Sarkeshik, M., Saylors, A., Schreiber, J., Shafer-Weaver, K., Shannon, V., Sharfman, W., Sharma, R., Sharon, E., Sherry, R., Silk, A. W., Simonson, C., Skondra, D., Suarez-Almazor, M. E., Thomas, C., Thompson, J. A., Trehu, E., Tresnan, D., Turner, M., Wang, Y., Wariabharaj, D., Waxman, I., Wiley, K., Wood, L., Zhang, L., Zheng, P.   +80 more
core   +2 more sources

PATRÓN DE PRESCRIPCIÓN DE AGONISTAS BETA-2 DE ACCIÓN CORTA Y POTENCIALES EFECTOS SOBRE EL CONTROL DEL ASMA: COHORTE ARGENTINA DEL ESTUDIO SABINA III

Revistas Argentina de Medicina, 2022
Conflictos de intereses El doctor Mattarucco es orador de AstraZeneca y ha realizado o realiza investigación clínica para AstraZeneca, GSK y Novartis. El doctor Goffredo ha recibido honorarios por charlas de AstraZeneca y GSK. El doctor Zunino es orador
Walter Mattarucco
doaj   +2 more sources

Guillain-Barre Syndrome and COVID-19 Vaccine: A Report of Nine Patients

Basic and Clinical Neuroscience, 2021
Introduction: Guillain-Barre Syndrome (GBS) is an autoimmune acute inflammatory demyelinating polyneuropathy usually elicited by an upper respiratory tract infection.
Narges Karimi, Reza Boostani, Farzad Fatehi, Akram Panahi, Ali Asghar Okhovat, Bentolhoda Ziaadini, Keivan Basiri, Siamak Abdi, Farnaz Sinaei, Mojtaba Rezaei, Gholamreza Shamsaei, Behnaz Ansari, Shahriar Nafissi   +12 more
doaj  

Cost comparison of asthma treatments in 12-week study : caution about matching and short observational follow-up [PDF]

, 2016
This review was funded by Observational and Pragmatic Research Institute Pte Ltd.Peer reviewedPublisher ...
Cifra, Alessandra, Law, Lisa M., McQueen, R Brett, Price, David B., van Boven, Job F. M.   +4 more
core   +3 more sources